/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

KALVISTA PHARMACEUTICALS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$14.3 0.0843(8.43%) KALV at 04 Dec 2025 04:36 PM Biotechnology
Lowest Today 13.515
Highest Today 16.45
Today’s Open 13.53
Prev. Close 13.52
52 Week High 17.28
52 Week Low 7.30
Day’s Range: Low 13.515 High 16.45
52-Week Range: Low 7.30 High 17.28
1 day return -
1 Week return +1.59
1 month return +36.05
3 month return -3.77
6 month return +8.04
1 year return +55.08
3 year return +183.17
5 year return -23.71
10 year return -

Institutional Holdings

VR Adviser, LLC 13.32

Suvretta Capital Management, LLC 9.81

TANG CAPITAL MANAGEMENT LLC 9.78

Vestal Point Capital LP 9.25

American Funds SMALLCAP World A 6.29

Capital World Investors 6.29

BlackRock Inc 6.19

Vanguard Group Inc 4.77

Woodline Partners LP 3.80

SILVERARC CAPITAL MANAGEMENT, LLC 3.63

Vanguard Total Stock Mkt Idx Inv 2.71

State Street Corp 2.67

Octagon Capital Advisors LP 2.52

APO Medical Opportunities R 2.31

Emerald Advisers, LLC 2.05

Ameriprise Financial Inc 1.87

Geode Capital Management, LLC 1.86

iShares Russell 2000 ETF 1.82

Emerald Mutual Fund Advisers Trust 1.52

Parkman Healthcare Partners LLC 1.34

International Biotechnology Ord 1.29

Dafna Capital Management LLC 1.15

SPDR® S&P Biotech ETF 1.13

Schroder Investment Management Group 1.10

MEDICAL BioHealth EUR Acc 0.89

Vanguard Institutional Extnd Mkt Idx Tr 0.81

Emerald Growth A 0.80

StemPoint Capital LP 0.77

Fidelity Small Cap Index 0.75

Bank of America Corp 0.73

iShares Russell 2000 Growth ETF 0.66

Principal SmallCap Growth I Instl 0.57

iShares Biotechnology ETF 0.46

Fidelity Extended Market Index 0.40

F/m Emerald Life Sciences Innovation ETF 0.39

Vanguard Russell 2000 ETF 0.36

Small Cap Growth / Emerald Fund SP 0.25

State St Russell Sm Cap® Indx SL Cl I 0.23

Vanguard Health Care ETF 0.20

Schwab Small Cap Index 0.19

Market Status

Strong Buy: 7

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 683.39 M

PB Ratio 41.3463

PE Ratio 0.0

Enterprise Value 543.27 M

Total Assets 250.77 M

Volume 6358313

Company Financials

Annual Revenue FY25:0 0.0M, FY24:0 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:12690000 12.7M

Annual Profit FY25:-941000 -0.9M, FY24:-86167000 -86.2M, FY23:null 0.0M, FY22:null 0.0M, FY21:12690000 12.7M

Annual Net worth FY25:-183444000 -183.4M, FY24:-126644000 -126.6M, FY23:-74853000 -74.9M, FY22:-68512000 -68.5M, FY21:-44494000 -44.5M

Quarterly Revenue Q4/2025:13692000 13.7M, Q3/2025:1426000 1.4M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q4/2024:0 0.0M

Quarterly Profit Q4/2025:12460000 12.5M, Q3/2025:836000 0.8M, Q2/2025:-15891000 -15.9M, Q1/2025:null 0.0M, Q4/2024:null 0.0M

Quarterly Net worth Q4/2025:-49482000 -49.5M, Q3/2025:-60096000 -60.1M, Q2/2025:-52226000 -52.2M, Q1/2025:-48509000 -48.5M, Q4/2024:-42268000 -42.3M

Fund house & investment objective

Company Information KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 270

Industry Biotechnology

CEO Mr. Benjamin L. Palleiko

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow